SP600125
Catalog No. A10860
SP600125是一种JNK抑制剂,对于JNK-1和JNK-2,IC50 = 40 nM,对于JNK-3,IC50 = 90 nM。
- Tetsuya Kouno, .et al. Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway, J Biol Chem, 2022, Jul;298(7):102056 PMID: 35605662
- Mark P Roberto, .et al. Mutations in the transcription factor FOXO1 mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis, Immunity, 2021, Aug 10;54(8):1807-1824.e14 PMID: 34380064
- Yang PM, .et al. p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma, Am J Cancer Res, 2019, Oct 1;9(10):2120-2139 PMID: 31720078
- Byungki Jang, .et al. The Peptidylarginine Deiminase Inhibitor Cl-Amidine Suppresses Inducible Nitric Oxide Synthase Expression in Dendritic Cells, Int J Mol Sci, 2017, Nov; 18(11): 2258 PMID: 29077055
- Yuki Haga, .et al. Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines, PLoS One, 2017, 12(3): e0174153 PMID: 28323861
- Jia-Shiuan Tsai, .et al. Cadmium Activates Multiple Signaling Pathways That Coordinately Stimulate Akt Activity to Enhance c-Myc mRNA Stability, PLoS One, 2016, 11(1): e0147011 PMID: 26751215
- Choe YJ, .et al. Nutlin-3 induces HO-1 expression by activating JNK in a transcription-independent manner of p53., Int J Oncol., 2014, 44(3):761-8. PMID: 24366007
Catalog Num | A10860 |
---|---|
M. Wt | 220.2 |
Formula | C14H8N2O |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 129-56-6 |
Synonyms | |
SMILES | C1=CC=C2C(=C1)C3=NNC4=CC=CC(=C43)C2=O |
SP600125是一种JNK抑制剂,对于JNK-1和JNK-2,IC50 = 40 nM,对于JNK-3,IC50 = 90 nM。
Targets
Target | Value |
---|---|
JNK1 | IC50: 40nM |
JNK2 | IC50: 40nM |
AuroraA | IC50: 60nM |
TrkA | IC50: 70nM |
JNK3 | IC50: 90nM |
FLT3 | IC50: 90nM |
MKK4 | IC50: 0.4μM |
MKK6 | IC50: 1.0μM |
PKB | IC50: 1.0μM |
MKK3 | IC50: 1.5μM |
PKCα | IC50: 1.5μM |
p56LCK | IC50: 4.3μM |
MKK7 | IC50: 5.1μM |
MEKK1 | IC50: >10μM |
ERK2 | IC50: >10μM |
p38β | IC50: >10μM |
PKA | IC50: >10μM |
PKC | IC50: >10μM |
PKCθ | IC50: >10μM |
Chk1 | IC50: >10μM |
EGF | IC50: >10μM |
IKK1 | IC50: >10μM |
IKK2 | IC50: >10μM |
In vitro (25°C) | DMSO | 43 mg/mL (195.25 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 5%DMSO+40%PEG300+5%Tween80+50%ddH2O | 1 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 45.41 mL | 227.07 mL | 454.13 mL |
0.5 mM | 9.08 mL | 45.41 mL | 90.83 mL |
1 mM | 4.54 mL | 22.71 mL | 45.41 mL |
5 mM | 0.91 mL | 4.54 mL | 9.08 mL |
*The above data is based on the productmolecular weight 220.2 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.